Singapore, June 2 -- 3billion, a South Korea-based AI-powered genomic diagnostics company, has announced the launch of 3B-NEO, a premium genomic newborn screening (gNBS) service designed to identify genetic risks before symptoms appear and support earlier medical intervention.

3B-NEO was developed in response to growing demand from international healthcare providers and global partners as genomic newborn screening gains momentum worldwide. The service is intended for all newborns and clinically actionable genetic insights focused on conditions where early medical intervention, monitoring, or treatment may meaningfully improve outcomes.

Rather than expanding the number of genes analysed, 3B-NEO was designed to prioritise actionable findi...